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Cardiovascular diseases (CVD) are the first cause of mortality in Western countries. CVD
include several pathologies such as coronary heart disease, stroke or cerebrovascular acci-
dent, congestive heart failure, peripheral arterial disease, and aortic aneurysm, among
others. Interaction between members of the tumor necrosis factor (TNF) superfamily and
their receptors elicits several biological actions that could participate in CVD.TNF-like weak
inducer of apoptosis (TWEAK) and its functional receptor and fibroblast growth factor-
inducible molecule 14 (Fn14) are two proteins belonging to theTNF superfamily that activate
NF-κB by both canonical and non-canonical pathways and regulate several cell functions
such as proliferation, migration, differentiation, cell death, inflammation, and angiogene-
sis. TWEAK/Fn14 axis plays a beneficial role in tissue repair after acute injury. However,
persistent TWEAK/Fn14 activation mediated by blocking experiments or overexpression
experiments in animal models has shown an important role of this axis in the pathological
remodeling underlying CVD. In this review, we summarize the role of TWEAK/Fn14 path-
way in the development of CVD, focusing on atherosclerosis and stroke and the molecular
mechanisms by which TWEAK/Fn14 interaction participates in these pathologies. We also
review the role of the soluble form of TWEAK as a biomarker for the diagnosis and prog-
nosis of CVD. Finally, we highlight the results obtained with other members of the TNF
superfamily that also activate canonical and non-canonical NF-κB pathway.
Keywords: atherosclerosis, stroke, biomarker,TWEAK,TNF superfamily
INTRODUCTION
Cardiovascular diseases (CVD) claim more lives worldwide than
any other, causing an estimated 17 million deaths worldwide
each year due to heart attacks and strokes. CVD included several
pathologies such as coronary heart disease, stroke or cerebrovas-
cular accident, congestive heart failure, peripheral arterial disease,
and aortic aneurysm, among others.
Cumulative evidence supports the important role of the tumor
necrosis factor (TNF) superfamily of proteins in the development
of CVD. The majority of ligands included in this family are synthe-
sized as type II transmembrane proteins with a common structural
motif (THD) that mediates self-trimerization and receptor bind-
ing (1). The extracellular domain of ligands can be cleaved to
generate soluble cytokines. Receptors are usually type I transmem-
brane glycoproteins characterized by the presence of extracellular
cysteine-rich domains (1). As their ligands, functional receptors
are also usually trimerics. Many TNF members, including TNF-
like weak inducer of apoptosis (TWEAK), activate the nuclear
factor kappaB (NF-κB) family of transcription factors (2). NF-κB
DNA-binding complex are homo- or heterodimers of five Rel pro-
teins: NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB, and c-Rel.
NF-κB dimers translocate to the nucleus and bind to DNA by two
different pathways, canonical or non-canonical NF-κB activation.
Binding of NF-κB to DNA activates the transcription of several
target genes that are implicated in the inflammatory response as
well as in cell proliferation, migration, and differentiation. All these
processes are closely related to pathological vascular remodeling.
TWEAK AND Fn14: STRUCTURE, EXPRESSION, AND
FUNCTION
The human TWEAK gene is located at chromosomal position
17p13.1 and encodes a 249-amino acid (aa) type II transmembrane
protein (3). TWEAK is expressed as a full-length, membrane-
bound protein (mTWEAK) and then is proteolytically processed
by furin, leading to the release of a 156-aa, 18 kDa soluble form
(sTWEAK) (3). The extracellular domain contains the receptor-
binding site and the intracellular domain contains a putative serine
phosphorylation site. In 2001, Fn14 was identified as the func-
tional TWEAK receptor using a cDNA expression library screening
approach (4). The human Fn14 gene is located at the chromosomal
position 16p13.3 (5), and encodes a 129-aa type I transmembrane
protein of 14 kDa that is processed into a mature form of 102-
aa (4). The extracellular domain contains the ligand-binding site
and the intracellular domain contains a TNFR-associated factor
(TRAF)-binding site (6) implicated in signal transduction induced
by TWEAK (7). A second receptor for TWEAK, CD163, has
recently been identified (8, 9). CD163 is a hemoglobin scavenger
receptor that is exclusively expressed by monocytes/macrophages
(10). It has been proposed that CD163 acts as a scavenger receptor
for TWEAK, thus preventing TWEAK from exerting its biologi-
cal actions by sequestering it from the environment. However, it
has been reported that recombinant CD163 failed to decrease cell
death induced by TWEAK in macrophages (11). The relevance
of TWEAK/CD163 interaction needs to be confirmed and more
studies are needed in order to determine whether this interaction
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takes place either in vitro or in vivo. In addition, the existence
of a third alternative receptor for TWEAK has been proposed,
since murine RAW264.7 cells differentiation induced by TWEAK
occurs in an Fn14-independent manner (12). However, no reports
describing this alternative receptor have been published and we
have observed that this monocytic/macrophage cell line expresses
functional Fn14 (Blanco-Colio, unpublished observation).
TNF-like weak inducer of apoptosis is expressed in several cell
types and tissues including the intestine, pancreas, lung, brain,
ovary, skeletal muscle, and vasculature, and to a lesser degree in
kidney and liver (3). Although TWEAK can be upregulated after
injury (13), changes in TWEAK gene expression are usually mod-
erated. By contrast, Fn14 expression in healthy tissues, including
the vasculature and heart, is usually low or undetectable, although
it is rapidly and highly upregulated under pathological conditions
as demonstrated in experimental models of chronic liver injury
(14), myocardial infarction (15), colitis (16), denervation-induced
skeletal muscle atrophy (17), restenosis after balloon injury (4),
atherosclerosis (18), autoimmune encephalomyelitis (19), acute
kidney injury (20), and cardiac dysfunction (21). Once Fn14 is
upregulated, TWEAK binds and causes Fn14 trimerization and
signal transduction (7). Although soluble TWEAK is responsi-
ble for the responses associated with Fn14, it has been recently
reported that full-length, membrane-anchored TWEAK can, in a
juxtacrine manner, bind to Fn14 on neighboring cells and acti-
vate the NF-κB signaling pathway, thus initiating the cellular
response (22).
Fn14 is upregulated by several growth factors, cytokines, and
interleukins in cells present in the injured vascular wall such as
endothelial cells, vascular smooth muscle cells (SMCs), and mono-
cyte/macrophages, but not in T and B lymphocytes (4, 18, 23, 24).
However, little is known of the regulatory mechanisms of Fn14
expression, and only the RhoA/ROCK pathway has been related to
Fn14 upregulation in cardiomyocytes (25). TWEAK protein can be
upregulated by PMA and IFN-γ in cultured peripheral mononu-
clear cells and natural killer cells (24, 26). Fn14 trimerization
induces the recruitment of TRAF2 and TRAF5 through its TRAF-
binding motif (PIEET). This motif is responsible for activating
different signaling pathways such as NF-κB and mitogen-activated
protein kinases (MAPK) (Figure 1) (7, 27). Activation of NF-κB
by TWEAK participates in the upregulation of several cytokines
implicated in the recruitment of inflammatory cells within the
injured vessel wall. Thus, TWEAK increases MCP-1 and RANTES
in SMCs (28). TWEAK also activates NF-κB in cultured Thp-1
monocytic cell line (29). In addition, TWEAK induces the expres-
sion of CCL19 and CCL21 in murine tubular cells (30), and
both cytokines are also expressed in atherosclerotic plaques of
ApoE-deficient mice, a model of hyperlipidemic-induced ather-
osclerosis (31). TWEAK also activates MAPK, although activa-
tion of ERK, c-Jun N-terminal kinase (JNK), or p38 pathways is
context-dependent. MAPK activation has been reported in several
cell lines, including Thp-1 monocytic cell line, endothelial cells,
cardiomyocytes, fibroblast, and others (23, 29, 32–34). There are
also different reports indicating that TWEAK activates PI3K/AKT
FIGURE 1 |TWEAK/Fn14 Signaling. TWEAK/Fn14 binding induces the
recruitment of cIAP and TRAF-1, 2, 3, and 5 and leads to activation of different
kinases such as mitogen-activated protein kinase kinases (MKK), transforming
growth factor β-activated kinase 1 (TAK1), and NF-κB inducing kinase (NIK).
TAK1 activates IKKβ and NIK activates IKKα, leading to the activation of
canonical or non-canonical NF-κB pathway, respectively. MMK are responsible
for the activation of c-Jun N-terminal kinase 1 (JNK1) and p38 MAPK, which
activate transcription factor activator protein-1 (AP-1). Increased activation of
NF-κB and AP-1 leads to the expression of specific target genes responsible
for TWEAK-mediated responses.
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in different cell types. Thus, TWEAK increases HMGB1 secretion
by cultured monocytes through PI3K activation (29). In addition,
TWEAK also activates transforming growth factor-β activated
kinase 1 (TAK1), implicated in NF-κB activation (35, 36) and
JNK, related with AP-1 activation (37). Overall, TWEAK activates
several signaling pathways that participate in the inflammatory
response of the injured tissues.
Several functions with potential pathological significance have
been related to TWEAK/Fn14 interaction and are dependent on
the cell type, microenvironment, and cell activation. However,
the basis for these differential responses is poorly understood.
TWEAK can regulate cell proliferation, migration, differentiation,
and death as well as tissue inflammation, angiogenesis, and regen-
eration (Figure 2) (3, 5, 38–40). The precise role of TWEAK in
different pathological situations needs to be characterized, since
TWEAK has beneficial or deleterious effects depending on the
stage of the disease (13, 41).
TWEAK AND ATHEROSCLEROSIS
Atherosclerosis is a multifactorial disease characterized by chronic
inflammation and excessive cell proliferation (Figure 3). Vascu-
lar lesions begin as a fatty streak in the subendothelial space of
large arteries. Endothelial cells acquire an activated phenotype
and express adhesion molecules such as intercellular adhesion
molecules (ICAMs), selectins, and vascular adhesion molecules
(VCAMs) that act as receptors for proteins expressed by leuko-
cytes (monocytes and lymphocytes and neutrophils). Recruitment
of monocytes to the subendothelial space causes their differentia-
tion to macrophages that uptake oxidized low density lipoproteins
(ox-LDL). In addition, chemokines and cytokines are secreted
by inflammatory cells and induce proliferation and migration of
SMCs from the media forming the neointima (42). The transition
of relatively early lesions to more advanced lesions is characterized
by the proliferation of SMCs and continuous uptake of ox-LDL
by macrophages, forming foam cells. In addition, SMCs synthe-
size extracellular matrix proteins that lead to the development
of the fibrous cap. This cap confers resistance to rupture by the
accumulation of collagen synthesized by SMCs. The continuous
ingestion of ox-LDL by foam cells induces death of these cells,
releasing of insoluble lipids and contributing to the formation of
the necrotic core characteristic of advanced lesions. Expression of
different proteases by macrophages and SMCs leads to degradation
of the fibrous cap, promoting plaque instability and subsequent
plaque rupture. Rupture of an atherosclerotic plaque may result
in the occlusion of an artery by the formation of a thrombus over
an atherosclerotic lesion, causing myocardial infarction, stroke, or
peripheral vascular disease (42).
The TWEAK/Fn14 axis plays an important role in several steps
of atherosclerotic plaque development including initiation, pro-
gression, destabilization/rupture, and subsequent thrombosis. As
commented, TWEAK is expressed in both the normal and patho-
logical arterial wall (18), but Fn14 is almost absent in healthy
arteries and its expression is highly upregulated in the carotid
artery (18), femoral atherosclerotic plaques (43), and in abdominal
aortic aneurysms (44). Different stimuli induce Fn14 expression in
resident and inflammatory cells present in the vascular wall. Thus,
pro-inflammatory cytokines (IL-1β and INF-γ), growth factors
(PDGF-BB, EGF, FGF-2), Angiotensin II, or α-thrombin increase
Fn14 expression in human and rat aortic SMCs (4, 18). In addition,
VEGF-A and FGF-2 increase Fn14 expression in human umbilical
FIGURE 2 | Pathological actions ofTWEAK/Fn14 interaction. Fn14 is
almost absent in healthy tissues. After injury, Fn14 is upregulated, facilitating
the interaction with its ligand TWEAK and its trimerization. In a context of
chronic injury, TWEAK/Fn14 interaction participates in pathological tissue
remodeling, promoting proliferation, migration, differentiation, apoptosis,
inflammation, angiogenesis, and matrix degradation.
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FIGURE 3 | Atherosclerotic plaque development. (A) Normal artery is
formed by a monolayer of endothelial cells, the tunica media of resident
smooth muscle cells embedded in an extracellular matrix, and the
adventitia that contains mast cells, fibroblasts, and microvessels.
(B) Adhesion of leukocytes to dysfunctional endothelium leads to their
migration into the vascular wall, forming the neointima. Monocytes
differentiate to macrophages and uptake lipids yielding foam cells. SMCs
migrate from the media, proliferate, and synthesize extracellular matrix
proteins such as collagen and elastin. SMCs and macrophages can die
and lipid derived from dead cells accumulates in the central region of the
plaque, the necrotic core that is covered by a fibrous cap. (C) Finally,
when the fibrous cap is broken, blood coagulant components trigger
thrombus formation, which occludes the lumen and interrupts the blood
flow.
endothelial cells (23) and human CD14+monocytes express Fn14
in response to INF-γ or PMA stimulation (24).
In the first steps of atherosclerosis development, adhesion
molecules and chemokines are responsible for the recruitment
of the inflammatory cells to the injured tissue. In vitro studies
have demonstrated that TWEAK/Fn14 interaction induces expres-
sion of adhesion molecules such as ICAM-1 and E-selectin in
human umbilical endothelial cells (45). Furthermore, TWEAK
increases interleukin-8 and MCP-1 secretion by endothelial cells
(45). Infiltrating cells secrete many cytokines that contribute to
SMCs migration and proliferation, favoring plaque progression.
In this sense, TWEAK/Fn14 interaction directly induces prolifer-
ation and migration of human and rat aortic SMCs (39, 45, 46)
and human endothelial cells (4, 23, 39, 45). These suggest that the
TWEAK/Fn14 axis could participate in neointimal thickening of
the pathological arterial wall. In fact, an in vivo study has reported
that Fn14 is upregulated in SMCs after balloon injury in mice (4).
The presence of a chronic inflammatory response is an impor-
tant phenomenon implicated in the development and progression
of atherosclerotic plaque. A key transcription factor implicated in
vascular inflammation is NF-κB. Activation of signal transduc-
tion mediated by NF-κB has been demonstrated at different stages
of atherosclerotic lesion development, from plaque formation to
plaque rupture (47). NF-κB is activated in SMCs, macrophages,
and endothelial cells in human atherosclerotic plaques (48–50).
Several molecules can activate this transcription factor in the
context of atherogenesis. Inflammatory stimuli such as members
of the TNF-α superfamily, IL-1, and ox-LDL induce NF-κB activa-
tion, and in consequence amplifying and maintaining a vascular
inflammatory response that facilitates atherosclerosis progression.
Activation of this transcription factor in endothelial cells enhances
the expression of adhesion molecules, chemokines, and metal-
loproteinases (MMP). These molecules coordinate the invasion
of inflammatory cells into the vascular wall, and enhance migra-
tion and proliferation of SMCs as well as the remodeling of the
extracellular matrix. Inflammatory cells and SMCs also increase
cytokine and MMP expression through NF-κB activation, perpet-
uating the inflammatory response. In particular, TWEAK activates
NF-κB in several cell types and increases the expression of pro-
inflammatory proteins such as IL-6, IL-8, MCP-1, and RANTES (7,
18, 27, 28, 46, 51, 52); these pro-inflammatory proteins are impli-
cated in atherogenesis. In addition, recombinant TWEAK injec-
tion increases atherosclerotic lesion size and inflammatory cell
content as well as NF-κB activation in the aortic root of hyperlipi-
demic ApoE-knockout mice (28). Moreover, anti-TWEAK mon-
oclonal antibody (mAb) therapy diminishes NF-κB activation as
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well as inflammatory response in ApoE-null mice, indicating that
endogenous TWEAK participates in atherogenesis (28). In addi-
tion, genetic deletion of TWEAK or treatment with anti-TWEAK
mAb diminished NF-κB activation, chemokines secretion and
inflammatory response in ApoE-deficient mice (53). The activa-
tion of NF-κB by TWEAK observed in this experimental model
was related to the canonical pathway, since p50/p65 dimers were
detected in the nuclei of cells within atherosclerotic plaques. Until
now, non-canonical NF-κB activation induced by TWEAK has not
been reported in atherosclerotic plaques.
TWEAK also increases the secretion of HMGB1 through
NF-κB activation in human M1 macrophages (29). HMGB1
is a DNA-binding cytokine that activates endothelial cells and
monocytes/macrophages to express pro-inflammatory cytokines,
chemokines, and adhesion molecules functioning as a criti-
cal mediator of inflammation (54). HMGB1 colocalizes with
Fn14 in the shoulder region of human atherosclerotic plaques,
a macrophage-rich area (29). In addition, systemic injection of
recombinant TWEAK augmented HMGB1 expression in ather-
osclerotic plaques of hyperlipidemic ApoE-null mice (29). The
importance of the finding that NF-κB can regulate HMGB1
release induced by TWEAK is because secreted HMGB1 may
in turn induce NF-κB activation, forming a loop between NF-
κB and HMGB1 that perpetuates vascular pro-inflammatory
effects related to TWEAK. These data support the notion that
TWEAK/Fn14 interaction has deleterious consequences in the
injured vascular wall.
Interestingly, it has been reported that TWEAK can modulate
macrophage size within atherosclerotic plaques (55). This find-
ing is related to the capacity of TWEAK to modulate lipid uptake
by macrophages. In fact, ApoE-deficient mice treated with Fn14–
Fc protein present smaller macrophages in their atherosclerotic
plaques, and treatment with anti-Fn14 or anti-TWEAK antibodies
or Fn14–Fc protein diminished macrophage uptake of modified
lipids in vitro (55).
The stability of the advanced atherosclerotic plaque depends on
the integrity of the fibrous cap that encloses its lipid core. Estab-
lished atherosclerotic lesions usually have a dense fibrous cap.
However, areas with sustained inflammation, macrophage accu-
mulation, and apoptosis are prone to rupture due to a weakening
of the fibrous cap. Deterioration of the fibrous cup is dependent on
the activity of MMP, which are collagen-degrading endopeptidases
that are secreted by SMCs and macrophages (56). As commented,
TWEAK and Fn14 are expressed in macrophages/foam cells rich
regions of atheroma plaques and colocalized with MMP (57).
Moreover, an activating anti-Fn14 antibody increases the expres-
sion of MMP-9 and MMP-1/13 in cultured monocytes (57). In
addition, anti-TWEAK mAb treatment diminishes MMP activity
in atherosclerotic plaques present in the aortic root of ApoE-
deficient mice (53). In addition, features of greater plaque stability
included augmented collagen/lipid ratio, reduced macrophages
content, and less presence of lateral xanthomas, buried caps,
medial erosion, intraplaque hemorrhage, and calcium content
have been observed in TWEAK/ApoE-double knockout mice or
in anti-TWEAK mAb treated ApoE-deficient mice (53). These
data indicate a potential role of TWEAK in extracellular matrix
degradation, which favors plaque instability.
Plaque rupture or erosion, and subsequent thrombosis, rep-
resent the main complications of atherosclerosis and could lead
to an acute cardiovascular event. Different molecules, such as
plasminogen activator inhibitor 1 (PAI-1) and tissue factor (TF),
are responsible for hemostasis and thrombosis (58). TF is the
principal initiator of the clotting cascade, while PAI-1 plays a
critical role in inhibiting fibrinolysis, and thereby the activity of
both molecules promotes thrombotic states and plays a crucial
role in vascular diseases (59). Fn14 colocalizes with PAI-1 and
TF in human carotid atherosclerotic plaques (60). In addition,
TWEAK increases TF and PAI-1 mRNA and protein expression
as well as activity in cultured human aortic SMCs (60). Fur-
thermore, systemic injection of recombinant TWEAK augmented
TF and PAI-1 expression in atherosclerotic plaques of ApoE-
deficient mice and, conversely, anti-TWEAK treatment diminished
the expression of both prothrombotic proteins (60). These data
indicate that TWEAK favors thrombus formation after plaque
rupture.
Overall, data obtained from in vitro and in vivo studies indi-
cate that TWEAK participates in different stages of atherosclerotic
plaque development from early stages to progression and subse-
quent plaque rupture that lead to an acute cardiovascular event,
such as myocardial infarction or stroke. Anti-TWEAK treatment
has the capacity to diminish pro-inflammatory response associ-
ated with atherosclerotic plaque progression and to alter plaque
morphology toward a stable phenotype.
TWEAK AND STROKE OUTCOME
Stroke is the third most common cause of death in the world
(61). A stroke, or cerebrovascular accident, causes rapid loss of
brain function due to a lack of oxygen; sudden death of brain cells
also takes place. The two main types of stroke include ischemic
(when a blood clot or thrombus forms) and hemorrhagic stroke.
The outcome after a stroke depends on where it occurs and how
much of the brain is affected. Smaller strokes may result in minor
problems, such as weakness in an arm or leg. Larger strokes may
lead to paralysis or death. Ischemic stroke triggers a cascade of
pathophysiological events such as energy depletion, excitotoxic-
ity, peri-infarct depolarization, inflammation, and apoptotic cell
death (62). The onset of the ischemic insult is followed by an
increase in the expression of pro-inflammatory molecules in the
ischemic tissue, which has been associated with neuronal death
and poor outcome.
Recent reports have shown the role of TWEAK/Fn14 axis after
an ischemic stroke. In fact, it has been reported that ischemic
stroke in humans (63) and experimental middle cerebral artery
occlusion (MCAO) in mice (64, 65) increase the expression of
both TWEAK and Fn14 in the ischemic tissue. In the central ner-
vous system (CNS), TWEAK and Fn14 are expressed mainly in
endothelial cells, perivascular astrocytes, microglia, and neurons.
There are two principal mechanisms by which TWEAK partici-
pates in stroke pathogenesis: neuronal apoptosis and breakdown of
the blood–brain barrier (BBB) (64, 66). It has been demonstrated
that in response to hypoxia/ischemia, TWEAK induces cell death
in neurons via NF-κB activation and PARP-1 and caspase-3 cleav-
age (64, 67). However, oxygen–glucose deprivation conditions did
not affect cell survival in neurons from Fn14- or TWEAK-deficient
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mice, indicating that cell death is mediated by the TWEAK/Fn14
interaction (67).
On the other hand, during cerebral ischemia, disruption of the
architecture of the neurovascular unit (NVU) results in an increase
in the permeability of the BBB with the development of cerebral
edema, which is a major cause of mortality among patients with
acute stroke. NVU is a dynamic structure consisting of endothelial
cells, the basal lamina, astrocytic end-feet processes, pericytes,
and neurons (68). The permeability of BBB is increased by pro-
inflammatory cytokines that act on the NVU under ischemic
conditions (69). It has been demonstrated that TWEAK has a detri-
mental effect on the structure of the NVU and the permeability
of the BBB in the early stages of cerebral ischemia. Recombinant
TWEAK injection directly into the brain induces activation of
NF-κB and MMP-9 expression, resulting in the disruption of the
structure of NVU and an increase in the permeability of BBB (70).
Furthermore, inhibition of TWEAK actions by Fn14–Fc decoy
receptor or Fn14 deficiency diminished cerebral ischemia-induced
increase in the permeability of the NVU. This protection was
associated with a faster recovery of locomotor activity (66).
Finally, intraperitoneal administration of anti-TWEAK mon-
oclonal antibodies (64) or intracerebroventricular administration
of Fn14–Fc decoy receptor (65) diminished the infarct size by
around 30–40% after 48 h of MCAO. In addition, Fn14-deficient
mice exhibited a 60% reduction in the volume of the ischemic
lesion following MCAO compared to wild-type animals (66).
Overall, TWEAK may play an important role during ischemia-
induced brain injury and its inhibition in the brain could be a novel
neuroprotective strategy for the treatment of ischemic stroke.
DIAGNOSTIC AND PROGNOSTIC VALUE OF SOLUBLE TWEAK
FOR CARDIOVASCULAR DISEASES
As commented above, TWEAK is expressed as a full-length,
membrane-bound protein and then is proteolytically processed
by furin, leading to the release of a 156-amino acid, 18 kDa
soluble form (sTWEAK) (3). Among the potential biomarkers
that could be differentially secreted by the pathological arterial
wall, sTWEAK was identified as a protein that is highly released
by normal arteries in comparison with carotid atherosclerotic
plaques (71). Plasma levels of sTWEAK were also found to be
diminished in patients with atherosclerosis compared to con-
trol subjects. The association of sTWEAK with the presence of
CVD or CVD-related diseases has been extensively validated in
other cohorts of individuals (Figure 4). Thus, sTWEAK con-
centrations were significantly reduced in patients with chronic
kidney disease (CKD) and/or type II diabetes (72). In addi-
tion, sTWEAK plasma concentrations were diminished in patients
undergoing hemodialysis compared to healthy subjects (73). In
addition, a gradual decrease in sTWEAK along with a reduc-
tion in estimated glomerular filtration rate in CKD patients has
been observed (74–76). Reduced levels of sTWEAK have also
been associated with the presence of coronary artery disease
(CAD) (25, 77), systolic heart failure (78), peripheral artery dis-
ease (PAD) (43), and aortic abdominal aneurysm (AAA) (44).
Finally, elevated circulating sTWEAK levels have been described
in patients after myocardial infarction (25) and stroke (63).
However, although the study of circulating proteins in sub-
jects suffering an acute event could unveil novel proteins impli-
cated in atherothrombosis, some of these proteins could be
Carotid Stenosis
(71)
Healthy Subjects (around 400 pg/mL in plasma)
(126)sTWEAK
Coronary Artery Disease
(78)
Heart Failure
(78)
Peripheral Arterial Disease
(43)
Chronic Kidney Disease
(74)
Diabetes
(72)
Abdominal Aortic Aneuryms
(44)
Hypertension
(127)
Myocardial Infarction
(125)
Stroke
(63)
FIGURE 4 | SolubleTWEAK as a biomarker of cardiovascular diseases.
Circulating sTWEAK concentrations are diminished in subjects with chronic
vascular damage including carotid stenosis, coronary artery disease,
peripheral artery disease, abdominal aortic aneurysm, heart failure, and
chronic kidney disease. Soluble TWEAK levels are also diminished in subjects
with cardiovascular risk factors such as diabetes or hypertension. However,
circulating sTWEAK levels are increased in patients suffering an acute
cardiovascular event (myocardial infarction or stroke).
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released by the tissue necrosis that takes place during an acute
event.
Two different surrogate markers of atherosclerosis such as flow-
mediated dilation (FMD) and intima/media thickness (IMT) have
been negatively associated with sTWEAK concentrations (71, 74,
75). As mentioned previously, endothelial dysfunction partici-
pates in the formation of vascular lesion (79). FMD described
the vasodilation of a conduit artery following an augmentation in
shear stress induced by an ischemia period. FMD provides us infor-
mation about the integrity of the endothelium (80). It has been
reported that sTWEAK plasma concentrations are negatively asso-
ciated with FMD in patients with CKD (74), persisting after adjust-
ment for factors related to FMD in CKD subjects such as blood
pressure, C-reactive protein, and estimated glomerular filtration
rate. This result was later confirmed in hypertensive CKD patients
(75). In addition, IMT can be measured non-invasively by means
of B-mode ultrasound, and increases in IMT have been associated
with an augmentation for future cardiovascular outcomes (81).
Thus, IMT has been negatively associated with sTWEAK concen-
trations in asymptomatic subjects (71) and in patients with CKD
(76, 82, 83), even after adjustment for traditional risk factors and
inflammatory biomarkers. Moreover, sTWEAK is associated with
atherosclerotic burden in CKD patients (83). However, IMT was
positively correlated with sTWEAK in renal transplant patients
(84, 85). Overall, the association of sTWEAK levels with differ-
ent surrogate markers of atherosclerosis indicates that this protein
could be a novel and independent biomarker of CVD.
Finally, different reports have indicated the potential use of
sTWEAK as a prognostic biomarker of CVD or CVD-related dis-
eases as well as its impact on survival. Thus, individuals in the
upper two tertiles of sTWEAK concentrations presented a lower
incidence of PAD (43). In addition, a decreased sTWEAK concen-
tration was significantly and independently associated with long-
term cardiovascular mortality in patients with lower-extremity
PAD (86). sTWEAK levels were also negatively related with AAA
size and AAA expansion rate after a 5-year follow-up,and sTWEAK
concentrations were predictive for subjects expanding more than
2 mm/year in AAA size (44). As for CKD, decreasing sTWEAK
concentration was associated with increased risk of cardiovascular
events independently of basic confounders (age, gender, estimated
glomerular filtration rate, C-reactive protein, diabetes, and car-
diovascular comorbidity) (76). However, high levels of sTWEAK
were associated with atherosclerosis in patients with systemic lupus
erythematosus (SLE), but not in control subjects (87). In addi-
tion, although sTWEAK plasma levels were diminished in HD
patients compared with controls, subjects belonging to the upper
tertile of sTWEAK presented a higher risk of all-cause and car-
diovascular mortality (73). This discrepancy could be due to the
existence of the known reverse epidemiology observed in HD
patients. Finally, sTWEAK also provides prognostic information
on subjects with heart failure. Subjects with chronic stable heart
failure with reduced sTWEAK plasma concentrations (78) present
a higher mortality rate than those with elevated sTWEAK levels. In
addition, the increase of sTWEAK concentrations diminishes the
risk of mortality in subjects with non-ischemic heart failure (88).
The mechanism/s by which sTWEAK is diminished in subjects
with vascular damage should be related to the expression of their
receptors. As commented, Fn14 expression is undetectable in the
vasculature in normal conditions (18). However, under patholog-
ical conditions including systemic inflammatory states, Fn14 is
highly upregulated in the vasculature, favoring sTWEAK binding
and retention in the pathological tissues (18, 57). In addition, the
expression of CD163 by M2 macrophages in pathological tissues
could be responsible for the decrease in sTWEAK, since CD163
can bind and internalize sTWEAK in vitro (8). On the basis of this
preceding literature, we speculate that the reduction in sTWEAK
concentrations in cardiovascular-related diseases could potentially
reflect either Fn14 binding or CD163 degradation (Figure 5).
However, this hypothesis needs to be tested in future studies. Over-
all, all these data reveal that sTWEAK could be a novel biomarker
of CVD. More large-scale studies to consolidate its usefulness are
required.
OTHER TNF SUPERFAMILY MEMBERS IMPLICATED IN
ATHEROTHROMBOSIS THAT ACTIVATE BOTH CANONICAL
AND NON-CANONICAL NF-κB PATHWAY
In recent years, the number of TNF receptors that are known
to potentially activate the non-canonical NF-κB pathway has
increased. These include, in addition to Fn14, CD40, B-cell acti-
vating factor receptor (BAFFR), lymphotoxin β receptor (LTβR),
receptor activator of NF-κB (RANK), and CD27 (89–93). Some of
these receptors have been implicated in different functions related
to the pathogenesis of atherosclerosis (Table 1).
The role of CD40 and its ligand CD40L in atherosclerosis has
been extensively studied. Both proteins are expressed in various
cell types implicated in atherogenesis such as platelets, endothelial
cells, monocytes/macrophages, and SMCs (110). CD40L induces
a broad inflammatory response in these cell types, including
increased expression of adhesion molecules, pro-inflammatory
cytokines, matrix degrading enzymes, and pro-coagulants (111,
112). Different groups have analyzed the role of CD40 and
CD40L in athero-prone mice by using diverse strategies such as
gene modification, blocking antibody treatment, or bone-marrow
transplantation (BMT). Thus, CD40L and ApoE double defi-
cient mice develop markedly reduced atherosclerosis (96, 98, 100).
In addition, treatment with neutralizing anti-CD40L antibodies
diminished atherosclerotic lesion size (98, 99) in LDLR-deficient
mice but failed to modify plaque size in ApoE-null mice (97).
The decrease of atherosclerotic plaques was associated with fea-
tures of higher plaque stability such as reduced macrophage
and lipid content as well as increased collagen deposition. The
effect of CD40L on atherosclerotic plaque progression seems
to be related with resident cells (endothelial and SMCs), since
BMT failed to modify atherosclerosis plaque size in LDLR−/−
mice (100, 101). However, a recent study describes that transfer
of CD40L−/− platelets into ApoE-null mice diminished ather-
osclerotic burden, an effect that results from the capacity of
platelets to synthesize higher amounts of CD40L (102). The
role of CD40 in atherosclerosis remains controversial. It has
been demonstrated that CD40 and ApoE double deficient mice
develop reduced levels of atherosclerosis when given a normal
chow diet compared with control animals (94). However, a sim-
ilar atherosclerotic burden was observed in CD40−/−LDLR−/−
mice on a high-cholesterol diet (95). These data could suggest
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FIGURE 5 | SolubleTWEAK in health and disease. Fn14 expression is
almost absent and minimal Fn14 activation is expected in the healthy
arterial wall. However, under pathological conditions, Fn14 expression is
highly upregulated in resident (smooth muscle cells) and inflammatory
cells (e.g., M1 macrophages). This increase facilitates the interaction
with sTWEAK and would trigger sTWEAK-dependent Fn14 signaling.
On the other hand, pathological tissues are infiltrated by anti-
inflammatory macrophages (M2) that express CD163, a scavenger
receptor of sTWEAK. The tissue consumption of sTWEAK by Fn14
interaction and CD163 degradation could be responsible for the
decrease in circulating sTWEAK levels observed in subjects with
atherosclerostic complications.
Table 1 | Effect ofTNF superfamily members that activate non-canonical NF-κB in experimental models of murine atherosclerosis.
TNF member Experimental approach/animal model Plaque size Reference
TWEAK Systemic rTWEAK injection in ApoE −/− mice Increased Muñoz-García et al. (28)
Blocking TWEAK in ApoE−/− mice Reduced Muñoz-García et al. (28)
Fn14 Blocking Fn14-Fc in ApoE −/− mice Reduced Schapira et al. (55)
CD40 CD40−/−/ApoE−/− double deficient mice Reduced Lutgens et al. (94)
CD40−/−/LDLR−/− double deficient mice No change Zirlik et al. (95)
CD40-TRAF6 blocking interaction in ApoE −/− mice Reduced Lutgens et al. (94)
CD40L CD40L−/−/ApoE−/− double deficient mice Reduced Lutgens et al. (96)
Blocking CD40L in ApoE−/− mice No effect Lutgens et al. (97)
Blocking CD40L in LDLR−/− mice Reduced Mach et al. (98), Schonbeck et al. (99)
BMT: CD40L−/− to LDLR−/− mice No change Bavendiek et al. (100), Smook et al. (101)
Transfer CD40L−/− platelets into ApoE−/− mice Reduced Lievens et al. (102)
BAFFR BAFFR−/−/ApoE−/− double deficient mice Reduced Kyaw et al. (103)
BMT: BAFFR−/− to LDLR−/− mice Reduced Sage et al. (104)
Blocking BAFFR antibody in ApoE−/− mice Reduced Kyaw et al. (105)
LTβR Blocking LTβR in ApoE−/− mice No change Gräbner et al. (106)
RANK OPG−/−/ApoE−/− double deficient mice Increased Bennett et al. (107)
Blocking Fc-OPG in ApoE−/− mice No change Morony et al. (108)
CD70 CD70 tg/ApoE*3 Leiden mice Reduced van Olffen et al. (109)
BMT, bone-marrow transplantation; OPG, osteoprotegerin.
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that CD40L mediates atherosclerosis development independently
of CD40 (95). However, specific interruption of CD40/TRAF6
interaction in ApoE-deficient mice diminished atherosclerotic
plaque size, indicating that CD40L/CD40 interaction participates
in atherosclerotic plaque development (94).
It has been demonstrated that the depletion of B cells dimin-
ished atherosclerosis in mice (113). The proatherogenic effect
of B cells is mainly driven by the B2 subset, which responds to
T-cell-dependent antigens and is part of the adaptive immune
response (114), while the atheroprotective effect is attributed to the
B1 subset, which responds to T-cell-independent antigens (115).
The survival and maturation of B2 lymphocytes depends on the
interaction of BAFF with its receptor, BAFFR (116). Genetic dis-
ruption of BAFFR induces a significant reduction in mature B2
cells without affecting B1a cells (117) and BAFFR/ApoE double
deficient mice present a reduced atherosclerotic plaque size and
macrophage content in their aortic root; this effect is also related
to a decrease in the number of B2 cells (103). In addition, BMT of
BAFFR deficient cells to LDLR−/− mice also leads to a reduction
in plaque size and inflammation (104). These data could sug-
gest that BAFFR is an interesting therapeutic target to limit the
development of atherosclerosis. Indeed, atherosclerosis develop-
ment is diminished in ApoE−/− treated with a BAFFR blocking
mAB (105).
Until now, the role of LTβR in atherosclerotic plaque devel-
opment is unclear. As commented above, cells present in
atherosclerotic lesions elicit persistent inflammation and trigger
immune adaptive response toward arterial wall-derived autoanti-
gens, such as ox-LDL or heat shock proteins. Coronary patients
with atherosclerosis present infiltrates of leukocytes in the adven-
titia, and the presence of adventitial B-cell follicle-like aggregates
in human aorta has been demonstrated (118). Moreover, adventi-
tia of ApoE-deficient mice also contains T- and B-cell aggregates.
These aggregates are the precursors of fully structured aorta ter-
tiary lymphoid organs (ATLOs) that contain a high number of
germinal centers, endothelial venules, regulatory T cells, and LN-
like conduits that connect ATLOs to medial SMCs (106). The
recruitment of T- and B-cell aggregates is dependent on CXCL13
and CCL21 secretion by SMCs through an LTβR-dependent sig-
naling pathway. The formation of ATLOs in ApoE-deficient mice is
restricted to abdominal aorta, and ATLOs are communicated with
medial SMC by conducts that serve as channels for both transport
of molecules (e.g., cytokines and chemokines) and soluble anti-
gens (119). Although it is conceivable that ATLOs play a role in
atherosclerotic plaque progression, ApoE-null mice treated with
anti-LTβR have not modified their atherosclerotic plaques. Future
gene deletion studies would help to understand the role of LTβR
and ATLOs in atherogenesis.
RANKL, which is expressed in human atherosclerotic plaques
(120), is capable of modulating different cell-type activities
through its receptor, RANK. RANK/RANKL interaction acti-
vates several intracellular signal transduction pathways such as
MAPKs and NF-κB (121). Several proatherogenic actions of
RANKL have been described. For example, RANKL induces MCP-
1 expression and secretion and matrix MMP activity in SMCs
(122). In addition, RANKL induces TF expression in macrophages
mainly through the cooperative action of NF-κB, AP-1, and Egr-1,
supporting a role of RANKL in the thrombogenicity of atheroscle-
rotic plaques (123). Furthermore, RANK, RANKL, and the decoy
receptor for RANKL osteoprotegerin (OPG) have been related
with vascular calcification, a crucial step for plaque destabilization
and rupture. In the absence of OPG, mice display vascular calci-
fication and present increased atherosclerotic plaque size (107).
However, treatment of LDLR-deficient mice with Fc-OPG dimin-
ished vascular calcification but failed to reduce atherosclerotic
plaque size (108).
Finally, CD27 is mainly found in T cells, and its ligand CD70 is
expressed in B cells, activated T cells, and dendritic cells. Interac-
tion of both proteins is necessary for the generation and long-term
maintenance of T-cell immune responses (124). Overexpression of
CD70 in B cells leads to an expansion of Th1 T cells in mice. This
indicates that these mice should have a proatherogenic pheno-
type. However, mice overexpressing CD70 are protective against
atherosclerosis development, possibly due to a reduced viability of
circulating monocytes (109). After these results, further research is
clearly needed to clarify the relevance of CD27 in atherosclerosis.
CONCLUDING REMARKS
The evidence gathered to date supports a role of the TWEAK/Fn14
axis in the development and outcome of atherosclerosis and
ischemic stroke. Data from experimental models make TWEAK
and its functional receptor Fn14 a promising target for the
treatment of patients with different CVD. Treatment with the
TWEAK neutralizing antibody or Fn14–Fc decoy protein has
demonstrated a beneficial effect on the development and pro-
gression of atherosclerotic plaques in mice. Furthermore, Fn14
deletion or anti-TWEAK administration diminished the volume
of the ischemic lesion after stroke, a related complication of
atherosclerotic plaque rupture. Although the use of monoclonal
antibodies offers – unlike small-molecule drugs – high target
specificity and allows less frequent, albeit parenteral, administra-
tion, there is a need for further drug development in this area,
including Fn14-specific antagonists.
The role of the TWEAK/Fn14 axis on pathological vascular
remodeling is not completely understood, and many questions
need to be answered. Could TWEAK induce vascular remodeling
in contexts other than atherosclerosis? As in stroke, could TWEAK
participate in the outcome of myocardial infarction? Could anti-
TWEAK therapy prevent atherosclerotic plaque development and
progression in the presence of different cardiovascular risk factors
such as diabetes or hypertension? Since TWEAK is also able to
interact with CD163 (8), could overexpression of CD163 dimin-
ish the proatherogenic effect of TWEAK? Statins can diminish
Fn14 expression in cultured SMCs (18), so could statins inhibit
atherosclerotic plaque progression induced by TWEAK? In the
near future, these and other potential questions could help us
to understand the role of this axis in different cardiovascular
pathologies.
Finally, the evidence accumulated indicates that sTWEAK could
be a biomarker for the diagnosis and prognosis of CVD. The reduc-
tion of sTWEAK plasma levels has been demonstrated in subjects
with different vascular affectations and its association with total
and cardiovascular morbidity and mortality has been reported
in different cohorts. However, after an acute cardiovascular event,
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sTWEAK concentrations are increased. Current and future studies
in large-scale populations will help us to determine the relevance
of sTWEAK as a CVD biomarker and its potential implementation
in clinical practice.
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